Stockscreener 앱 받기
0.8862
3.18%
-0.0438
전일 마감가:
$0.93
열려 있는:
$0.95
하루 거래량:
407.97K
Relative Volume:
2.69
시가총액:
$50.04M
수익:
-
순이익/손실:
$-131.52M
주가수익비율:
-0.4979
EPS:
-1.78
순현금흐름:
$-107.56M
1주 성능:
+6.92%
1개월 성능:
+14.66%
6개월 성능:
-21.02%
1년 성능:
-84.45%
1일 변동 폭
$0.77
$0.98
1주일 범위
$0.77
$1.02
52주 변동 폭
$0.6101
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
명칭
Prelude Therapeutics Inc
전화
(302) 467-1280
주소
175 INNOVATION BOULEVARD, WILMINGTON
PRLD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
0.8862 | 52.51M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.20 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.00 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.53 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.63 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.67 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 개시 | Jefferies | Buy |
| 2022-03-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-28 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-10-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-26 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2020-11-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-10-20 | 개시 | Goldman | Neutral |
| 2020-10-20 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
Buy Signal for Prelude Therapeutics Incorporated Stock Key Technical Indicators to WatchMarket Forecast Summary Over Multi-Year Period - Newser
SRx Health Solutions Inc. recovery potential after sell offPrice Action Summary and Entry Strategy Guide - Newser
Using data models to predict Prelude Therapeutics Incorporated stock movementFree Growth Focused Entry Plan Suggestions - Newser
What is the dividend policy of Prelude Therapeutics Incorporated stockBuild your wealth with consistent stock growth - jammulinksnews.com
What makes Prelude Therapeutics Incorporated stock price move sharply Entry Timing Tracker with Alert Accuracy - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionPredictive Screener for Daily Trade Watch - Newser
Is it the right time to buy Prelude Therapeutics Incorporated stockDiscover stocks with strong growth potential - jammulinksnews.com
Prelude Therapeutics Incorporated Stock Performance After Earnings: Historical InsightsWeekly Big Movers - Newser
What makes Prelude Therapeutics Incorporated stock price move sharplyFree Access to Community - metal.it
Prelude Therapeutics (NASDAQ:PRLD) Trading 2% Higher – Time to Buy? - Defense World
What drives Prelude Therapeutics Incorporated stock priceUnmatched profit growth - PrintWeekIndia
Is Prelude Therapeutics Incorporated a good long term investmentSkyrocketing investment returns - PrintWeekIndia
What analysts say about Prelude Therapeutics Incorporated stockRapid wealth accumulation - Autocar Professional
Will Prelude Therapeutics Incorporated stock split in the near futureExplosive trading opportunities - jammulinksnews.com
Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study - TipRanks
Prelude Therapeutics Incorporated Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com
what makes prelude therapeutics incorporated stock price move sharplyFree Investment Community - Newser
Is Prelude Therapeutics Incorporated stock a good hedge against inflation10x Return With Managed Risk - Newser
How Prelude Therapeutics Incorporated stock performs during market volatilityFree Smart Investment Opportunities - Newser
Prelude Therapeutics’ PRT7732 Study: A Potential Game-Changer for SMARCA4 Mutations - TipRanks
Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors - TipRanks
Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study - TipRanks
Prelude Therapeutics Inc (PRLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prelude Therapeutics Inc 주식 (PRLD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
0.79%
1.35%
자본화:
|
볼륨(24시간):